P53 Reactivation via MDM2 Inhibition with Milademetan: Phase 3 Data in 1H 2023 (Rain Therapeutics)

MDM2 is a key regulator of p53, the protein responsible for tumor suppression and apoptosis — an intractable, yet undruggable target. Previous attempts to drug MDM2 have been met with significant toxicities issues. The MDM2 oral inhibitor milademetan has the potential to address these issues and in doing so may open the door to treating multiple tumor types, as identified by standard molecular testing. Indeed, studies with milademetan have demonstrated promising preliminary results in liposarcoma. Let the Wall Street veteran, CEO Avanish Vellanki, walk you through the RAIN.